Agoracom Blog Home

Posts Tagged ‘#psychedelic’

Red Light Holland $TRIP.ca $TRUFF Talks Up New Wisdom Truffle Design $RVV.ca $PSYC $FTRP $BUZZ

Posted by AGORACOM-Eric at 1:46 PM on Tuesday, March 2nd, 2021
https://i.ibb.co/ZdKv64V/Red-Light-Holland-Square.jpg
  • RED LIGHT HOLLAND LAUNCHES NEW LOGO AND INTERACTIVE WISDOM TRUFFLE COMPANION CREATED BY INTERNATIONALLY RENOWNED & AWARD-WINNING DESIGNER KARIM RASHID

Red Light Holland Corp. has revealed the company’s interactive Wisdom Truffle and new logo carefully and creatively designed by renowned designer and head of design for Red Light Holland, Karim Rashid.

The Wisdom Truffle will be produced in three different models which is expected to be sold across the world in Q4 2021, and it will be able to be pre-ordered on the Company’s website by the end of March 2021. Each model will support a different aspect of Red Light Holland’s iMicro healthy lifestyle and work in conjunction with Red Light Holland’s iMicro Journal WebApp (currently in use) and the Company’s completed immersive AR/VR apps.

“While focusing on our core business, our goal is also to create alternative revenue streams while building a global brand that is electric, alive and genuinely connects – which then encourages a lifestyle of healthy daily habits, including disconnecting from technology and reconnecting with nature and ourselves for mental clarity,” said Red Light Holland CEO and Director Todd Shapiro. “I’m amazed to be part of such a creative team that is combining Karim Rashid’s designs and Radix Motion’s technology. Together we are kicking ass with this unique combination of tech meeting real life through creative minds from all sides.

The Red Light Holland team is proud to help you see things differently.”Wisdom Truffle Companion Image 3

https://orders.newsfilecorp.com/files/2017/75834_8f45f1f054cfcac8_002full.jpg

“The design of the Wisdom Truffle companion promotes positivity and provides comfort. The Wisdom Truffle is also an incredible art piece that’s a great conversation starter around finding a healthier balance with our use of technology. Something we need now more than ever,” said Karim Rashid. “The three model sizes will fit different, use cases and together can transform any environment, bringing light, music and interactivity. The new logo reflects the Wisdom Truffle becoming Red Light Holland’s brand ambassador and it truly represents all of us proudly.”

Read More:https://agoracom.com/ir/RedLightHolland/forums/discussion/topics/756386-red-light-holland-launches-new-logo-and-interactive-wisdom-truffle-companion-created-by-internationally-renowned-award-winning-designer-karim-rashid/messages/2306069#message

Red Light Holland $TRIP.ca $TRUFF iMicrodose Pack Receives Authorization for the First Legal Import and Sale of Psilocybin Truffles to Brazil $RVV.ca $PSYC $FTRP $BUZZ

Posted by AGORACOM-Eric at 8:53 AM on Thursday, February 25th, 2021
https://i.ibb.co/ZdKv64V/Red-Light-Holland-Square.jpg
  • iMicrodose packs, which contain 15g of Psilocybin Truffles, to be legally imported to Brazil
  • To be imported and sold in Brazil for Medical use
  • Approval and shipment represent a significant advancement in opening the legal and medically approved market for psilocybin in Brazil

Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC: TRUFF) (“Red Light Holland” or the “Company“), an Ontario-based corporation engaged in the production, growth and sale of a premium brand of magic truffles to the legal, recreational market within the Netherlands, is extremely pleased to announce that Anvisa, Brazil’s National Health Regulatory Agency, has granted authorization for the Company’s iMicrodose packs, which contain 15g of Psilocybin Truffles, to be legally imported to Brazil via the ‘named patient import process’ for prescribed medical patient use.

“We are grateful for our collaborative relationship with Disruptive Pharma who worked closely with the Brazilian Health Regulatory Agency to secure authorization to import Red Light Holland’s iMicrodose packs, with our natural-occurring branded Psilocybin Truffles, to be imported and sold in Brazil for Medical use, as our branded iMicrodose packs have officially been prescribed by a doctor to a patient in Brazil,” said Todd Shapiro, CEO and Director of Red Light Holland. “This is a monumental day for the Company, and we are so proud to be a part of providing legal access of psilocybin to Brazil and for the first time having our product prescribed by a physician for medical use.”

Red Light Holland’s iMicrodose packs have been shipped to Disruptive Pharma’s MyPharma2Go logistics hub in the Netherlands to start their journey to Brazil. Once landed in Brazil, MyPharma2Go is expected to deliver the iMicrodose packs to a Brazilian patient as they have been pre-prescribed by a physician, before the end of March 2021.

This approval and shipment represent a significant advancement in opening the legal and medically approved market for psilocybin in Brazil, a country with a population of over 200 million people. Shapiro added: “This early process working alongside Disruptive Pharma’s MyPharma2Go.com, a large Brazilian online pharmaceutical and supplement distributor, has been an absolute pleasure and one we are thankful for. We are pleased to do our part to potentially be a part of positive change in Brazil, and to steal a line from Neil Armstrong: This is one micro step for man, one macro leap for mankind.”

Red Light Holland and Disruptive Pharma continue to work towards finalizing their proposed joint venture structure and agreement, as previously disclosed in the Company’s news release dated December 14, 2020. In consideration for Disruptive Pharma having met these initial milestones, the Company has agreed to issue to Disruptive Pharma, 3,000,000 common share purchase warrants, each warrant is exercisable into one common share of the Company at a price of $0.50 per share for a period of 2 years. 750,000 of these warrants have vested immediately based on Disruptive Pharma having fulfilled these milestones, the balance vest upon future milestones being met. These warrants and any underlying shares issued upon exercise, are subject to a statutory hold period of 4 months and 1 day.

Read More: https://agoracom.com/ir/RedLightHolland/forums/discussion/topics/756065-red-light-holland-imicrodose-pack-receives-authorization-for-the-first-legal-import-and-sale-of-psilocybin-truffles-to-brazil/messages/2305343#message

Red Light Holland $TRIP.ca Announces Increase in Bought Deal Equity Financing to $10 Million $RVV.ca $PSYC $FTRP $BUZZ

Posted by AGORACOM-Eric at 9:57 AM on Wednesday, February 3rd, 2021
https://i.ibb.co/ZdKv64V/Red-Light-Holland-Square.jpg
  • Doubles the size of the bought deal to $10 million

Red Light Holland Corp. (“Red Light Holland” or the “Company”) (CSE:TRIP), an Ontario-based corporation positioning itself to engage in the production, growth and sale of a premium brand of magic truffles to the legal, recreational market within the Netherlands, is pleased to announce that it has entered into an amended agreement with Eight Capital, pursuant to which Eight Capital has now agreed to buy, on a bought deal basis, 23,000,000 units (“Units”) at a price of $0.44 per Unit (the “Issue Price”), for gross proceeds of $10,120,000 (the “Offering”).

The Company has agreed to grant Eight Capital an over-allotment option to purchase up to an additional 15% of the Units at the Issue Price, exercisable in whole or in part, at any time on or prior to the date that is 30 days following the closing of the Offering. If this option is exercised in full, an additional approximately $1,500,000 will be raised pursuant to the Offering and the aggregate proceeds of the Offering will be approximately $11,600,000.

Read More:https://agoracom.com/ir/RedLightHolland/forums/discussion/topics/754534-red-light-holland-announces-increase-in-bought-deal-equity-financing-to-10-million/messages/2301795#message

Red Light Holland $TRIP.ca Announces $5 Million Bought Deal Equity Financing $SHRM.ca $RVV.ca $MMED $PLNT.ca $HALO.ca $PSYC.ca

Posted by AGORACOM-Eric at 8:41 AM on Wednesday, February 3rd, 2021
https://i.ibb.co/ZdKv64V/Red-Light-Holland-Square.jpg

Red Light Holland Corp. (“Red Light Holland” or the “Company”) (CSE:TRIP), an Ontario-based corporation positioning itself to engage in the production, growth and sale of a premium brand of magic truffles to the legal, recreational market within the Netherlands, is pleased to announce that it has entered into a letter of engagement with Eight Capital, under which Eight Capital has agreed to purchase, as sole bookrunner and underwriter, 11,600,000 units of the Company (the “Units”), on a “bought deal” basis pursuant to a filing of a short form prospectus, subject to all required regulatory approvals, at a price per Unit of $0.44 (the “Issue Price”) for gross proceeds of $5,060,000 (the “Offering”).

The Company has agreed to grant Eight Capital an over-allotment option to purchase up to an additional 15% of the Units at the Issue Price, exercisable in whole or in part, at any time on or prior to the date that is 30 days following the closing of the Offering. If this option is exercised in full, an additional approximately $750,000 will be raised pursuant to the Offering and the aggregate proceeds of the Offering will be approximately $5,750,000.

Each Unit will be comprised of one common share of the Company (a “Common Share”) and one Common Share purchase warrant (a “Warrant”). Each Warrant shall entitle the holder thereof to purchase one Common Share at an exercise price of $0.70, for a period of 36 months following the closing of the Offering. If the daily volume weighted average trading price of the Common Shares on the Canadian Securities Exchange for any 10 consecutive days equals or exceeds $1.52, the Company may, upon providing written notice to the holders of the Warrants, accelerate the expiry date of the Warrants to the date that is 30 days following the date of such written notice.

Read More: https://agoracom.com/ir/RedLightHolland/forums/discussion/topics/754514-red-light-holland-announces-5-million-bought-deal-equity-financing/messages/2301766#message

Red Light Holland $TRIP.ca $TRUFF Announces the Red Light Holland “Give-You-A-Job” Contest $SHRM.ca $RVV.ca $MMED $PLNT.ca $HALO.ca $PSYC.ca

Posted by AGORACOM-Eric at 8:49 AM on Monday, February 1st, 2021
https://i.ibb.co/ZdKv64V/Red-Light-Holland-Square.jpg
  • Monday, February 8th the Company will launch the Red Light Holland “Give-You-A-Job” contest.

Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC: TRUFF) (“Red Light Holland” or the “Company“), an Ontario-based corporation engaged in the production, growth and sale of a premium brand of magic truffles to the legal, recreational market within the Netherlands, is pleased to announce that on Monday, February 8th the Company will launch the Red Light Holland “Give-You-A-Job” contest.

“We are the People’s Company and we are grateful to our supporters,” said Todd Shapiro, CEO and Director of Red Light Holland. “Now that we have over $20 million1 in the bank, we have a dedicated budget committed to building our team. The Logo-Redesign contest was a huge success, so we thought, instead of posting on the same old job search sites, which, in my opinion, can never highlight ‘passion’ and ‘love’ of what one wants to do – why not offer positions to our supporters and believers – you know, the #RedLightArmy. We are confident there are highly skilled individuals within this loyal and passionate group who will be amazing additions to our phenomenal team. We are excited about the potential to work with people who are talented, proud, fearless, disruptive and have a romance with the knowledge and belief in the future of psychedelics.”

Read More: https://agoracom.com/ir/RedLightHolland/forums/discussion/topics/754326-red-light-holland-announces-the-red-light-holland-give-you-a-job-contest/messages/2301352#message

Red Light Holland $TRIP.ca Announces Closing of $9.77 Million Bought Deal Financing $SHRM.ca $RVV.ca $MMED $PLNT.ca $HALO.ca $PSYC.ca

Posted by AGORACOM-Eric at 10:48 AM on Thursday, January 28th, 2021

Red Light Holland Corp. (CSE: TRIP) (“Red Light Holland” or the “Company“), an Ontario-based corporation engaged in the production, growth and sale of a premium brand of magic truffles to the legal, recreational market within the Netherlands, is pleased to announce that it has closed its previously announced bought deal short form prospectus offering, including the exercise in full of the underwriter’s over-allotment option (the “Offering“). In connection with the Offering, the Company issued 38,334,100 units of the Company (the “Units“) at a price of $0.255 per Unit, for aggregate gross proceeds of $9,775,195. The Offering was conducted by Eight Capital (the “Underwriter“).

“To have Red Light Holland – The People’s Company, being supported by ‘The Suits’ alongside our new and existing shareholders truly strengthens our Psychedelic Movement and our growth. We are so grateful for all of our loyal supporters and we now have over $20 million[1] of capital available which is incredible! This funding will enable us to fully execute on our business plan and the Red Light Holland team will continue working hard towards our goal of developing a leading brand in this emerging industry. Our mission continues – providing legal and responsible adult access now,” said Todd Shapiro, CEO and Director of Red Light Holland.

Read More:https://agoracom.com/ir/RedLightHolland/forums/discussion/topics/754141-red-light-holland-announces-closing-of-9-77-million-bought-deal-financing/messages/2300783#message

Psychedelics: From Woodstock to Walgreens SPONSOR: Red Light Holland $TRIP.ca $SHRM.ca $RVV.ca $MMED $PLNT.ca $HALO.ca $PSYC.ca

Posted by AGORACOM-Eric at 9:34 AM on Friday, January 22nd, 2021

SPONSOR: Red Light Holland (CSE: TRIP) is engaged in the production, growth and sale (through existing Smart Shops operators and an advanced e-commerce platform) of a premium brand of magic truffles to the legal, recreational market within the Netherlands. Learn more.

https://i.ibb.co/ZdKv64V/Red-Light-Holland-Square.jpg

Psychedelic experience is only a glimpse of genuine mystical insight, but a glimpse which can be matured and deepened by the various ways of meditation in which drugs are no longer necessary or useful. If you get the message, hang up the phone. For psychedelic drugs are simply instruments, like microscopes, telescopes, and telephones. The biologist does not sit with eye permanently glued to the microscope, he goes away and works on what he has seen…

– Alan Watts

What Are Psychedelics?

The term “psychedelic” was first used by psychiatrist Humphry Osmond in 1956 during a discussion with Aldous Huxley, the famous author and pioneer of psychedelic consumption. The etymology of the word is derived from the Greek meaning “mind-manifesting”. A more robust definition of the word was developed by Grinspoon and Bakalar:

“a psychedelic drug is one which, without causing physical addiction, craving, major physiological disturbances, delirium, disorientation, or amnesia, more or less reliably produces thought, mood, and perceptual changes otherwise rarely experienced except in dreams, contemplative and religious exaltation, flashes of vivid involuntary memory and acute psychoses.”

– Grinspoon and Bakalar (Multidisciplinary Association for Psychedelic Studies)

Notice that this definition excludes drugs like heroin, methamphetamine, cocaine, and THC, all of which can produce psychedelic effects but are not their primary effect.

2D structural formula and 3D models of Lysergic acid diethylamide (LSD), also known as “acid”.

History of Psychedelic Use

Sacred Ceremonies

Psychedelics have been regarded as sacred plants since the dawn of civilization, with the earliest known consumption of plants containing psychedelic agents occurring in 5000 BCE in Southeastern Algeria . The use of psychedelics to conjure religious experiences was universal amongst humans, as evidenced by depictions of sacred ceremonies centered on these mind-expanding substances found across the globe. The plants which contain these psychedelic agents include mushrooms, cacti, morning glory vines, and even some grasses. Psychedelic ceremonies have shaped many religions and are still used throughout the world.

Examples include:

  • “Soma” found in Sanskrit texts of Hinduism, derived from the Amanita Muscaria mushroom (~1500 BCE)
  • Ergot fungus used in the Eleusinian Mystery Rites of the Greeks, the active ingredient being similar to the synthetic LSD (“acid”) (~2000 BCE)
  • Psylocibin mushrooms used in the town of Villar del Humo in Spain (earliest evidence of psychedelic mushrooms in Europe, ~4000 BCE)
  • Peyote used by the Native Americans, found in the Shumla Caves (~3700 BCE)
  • Modern day usage of psychedelics includes Ayahuasca in the Amazon (active ingredient is DMT), Peyote by the Native Americans in the Western USA, and the global use of Psilocybin.

Earliest depiction of a psychedelic ceremony. Frescos of mushroom-holding shamans were found in caves on the Tassili plateau of Southeastern Algeria.

Sacred ceremonies were (and are) typically led by a Shaman, a respected elder who plays the role of doctor, therapist, and priest. Along with administration of the psychedelic plants, the Shaman provides “non-drug” support to his “patient” to amplify and control the mind-enhancing effects of the compounds. The dreamlike states that the Shaman can invoke brings forth the shadows that lurk in the subconscious into the spotlight of the conscious mind. I have heard frequent users of psychedelics in religious contexts explain the experience as 10 years’ worth of therapy crammed into 4 hours… you are forced to confront your demons and reconcile your angst. These ceremonies are vital to preserving ancient cultures and should be respected as integral parts of religion Now that’s heavy stuff. Let’s move on to something a bit lighter…

Discovery of LSD

Lysergic Acid Diethylamide (“LSD”) is probably the most widely recognized psychedelic substance. Colloquially known as “acid”, LSD was first synthesized in 1938 at the Sandoz research labs in Basel, Switzerland, by Dr. Albert Hofmann. While conducting research into ergot, a fungus that grows on grains and was the cause of mass poisoning in the middle ages (“Saint Anthony’s fire”), Dr. Hofmann realized that the panic-inducing effects of ergot consumption could be attributed to specific alkaloids present in the plant. The basic group of the primary alkaloid (ergobasine) was discovered to be lysergic acid, and several modifications were made to produce LSD as it is known today (“LSD-25”, the 25th modification to the lysergic acid base). The first clinical applications of LSD-25 were tested on controlling blood flow loss in the uterus, but it was quickly determined that the synthetic LSD was not as effective as the naturally occurring substance in ergot. Dr. Hofmann abandoned his research until he accidentally ingested a microscopic amount of LSD via absorption through his skin. According to popular lore, Dr. Hofmann then took an interesting bike ride home during which he was not completely sure whether he was actually moving… upon examination by a medical doctor it was determined that Dr. Hofmann experiencing the full-blown effects of the first acid trip, characterized by pleasant visual distortions and intensely bright colors.

Psychedelics in the Clinic

The LSD-25 compound was tested by other researchers at Sandoz for its potential medicinal benefits. Marketed under the name “Delysid”, Sandoz’s LSD-25 was approved for psychiatric use and disseminated to psychiatrists worldwide. Predicated on the large-scale manufacturing capabilities in the post-WWII 20th century, and the emerging field of psychiatric research and treatment, interest in LSD-25 skyrocketed and hit the public consciousnesses.

Much of the early research into using LSD-25 as a catalyst for inducing changes in brain states was conducted by the CIA in a project known as “MK-ULTRA”. The CIA speculated that LSD could be used as a “truth drug” to assist in interrogations, and in 1953 the agency was given formal approval to test a wide range of psychedelic substances as possible interrogation “enhancers” (LSD being the prime candidate). The MK-ULTRA story is fascinating, fraught with corruption and mysterious deaths, yet the conclusion of the program was uninspiring: LSD-25 is a very poor truth serum and the effects were largely unpredictable between recipients.

Meanwhile, psychiatrists were developing two new models of psychedelic-assisted therapy: psychedelic therapy and psycholytic therapy. Both paradigms involved the use of LSD in treatment, but psycholytic therapy was much a softer approach that involves substantially lesser amounts of LSD than psychedelic therapy, with the goal of bringing about gradual change in personality over the course of months. The underlying theory of psycholytic therapy was based upon Freudian psychoanalysis, with the idea that LSD served as a priming agent by inhibiting the portion of the brain responsible for the ego-identity. LSD was intended to break down the ego and render the patient in a naïve, infantile state of feeling, often associated with derealization and mystic experience. Contrastingly, psychedelic therapy was an attempt to wage total war on the brain using extremely high amounts of LSD dosed in a single session, with the goal of bringing about a symptomatic change in behavior (poorly defined). The original theory was that extremely high doses of LSD could shock alcoholic patients and scare them away from drinking permanently by giving them a horrific experience… but to the clinicians’ surprise the patients experienced very pleasant effects. Emphasis of psychedelic therapy switched to creating a mystical type of experience to re-wire the patient’s brain in a way directed by the psychiatrist or therapist.

“Many people remember vaguely that LSD and other psychedelic drugs were once used experimentally in psychiatry, but few realize how much and how long they were used. This was nota quickly rejected and forgotten fad. Between 1950 and the mid-1960s there were more than a thousand clinical papers discussing 40,000 patients, several dozen books, and six international conferences on psychedelic drug therapy. It aroused the interest of many psychiatrists who were in no sense cultural rebels or especially radical in their attitudes.”

– Grinspoon and Bakalar, 1979

Turn On, Tune in, Drop Out

The popularization of LSD as a substrate for religious-like experiences in American culture was pioneered by the likes of Aldous Huxley, Gerald Heard, Timothy Leary, and Richard Alpert (later to be known as Ram Daas). Their collective work chronicled the psychonaut’s journey through time and space, blending Eastern philosophy with Western ideas. These writings were often written like a piece of “gonzo journalism”, the focus being on the author’s own lived experience. These first-person essays galvanized the public’s curiosity into using psychedelics to unlock latent mental bandwidth and enhance the sensory world.

“The really important facts were that spatial relationships had ceased to matter very much and that my mind was perceiving the world in terms of other than spatial categories. At ordinary times the eye concerns itself with such problems as where? — how far? — how situated in relation to what? In the mescaline experience the implied questions to which the eye responds are of another order. Place and distance cease to be of much interest. The mind does its perceiving in terms of intensity of existence, profundity of significance, relationships within a pattern.”

– Aldous Huxley, The Doors of Perception

Back in the day, loose regulations around controlled substances allowed psychiatrists to give people LSD with little oversight in questionable environments, leading to a surge in recreational use beginning in 1962. FDA regulations began to tighten around the same time, and the introduction of the Kefauver-Harris Drug Amendment forced Sandoz to limit the supply of LSD to physicians at the National Institute of Mental Health. Not long after, the 1965 Drug Control Amendment forced Sandoz to stop supplying LSD entirely (it was later deemed a Schedule 1 substance by the FDA, 1970). As the counter-culture movement of the ‘60s took off, illegal manufacturing and distribution of LSD kept the hippy generation satisfied.

State-of-the-Science

Mechanism of Action

The discovery of the psychedelic effects of LSD in 1943 was followed by the detection of serotonin in the brains of mammals (1953) . Comparison of the serotonin structure with that of LSD revealed a striking similarity in the scaffold of the molecules. Could LSD’s mechanism of action in the brain rely on the same neuronal pathways that serotonin signals through? It was quickly discovered that the mind-altering effects of LSD were attributed to an interference in serotonin signaling in the brain (via competition for the 5-HT2 serotonin receptors) . This discovery catapulted research into the role of serotonin in neuroscience.

Similarity in the serotonin and LSD molecular structures

Clinical Research

The clinical research on psychedelics of the 20th century ended with the Controlled Substances Act of 1970. Fortunately, the recent resurgence in interest into the medical benefits of psychedelics has led to the renewal of experimentation in humans.  On March 5, 2019, esketamine (Janssen Pharmaceuticals, a J&J company) became the first approved psychedelic drug by the FDA for the treatment of psychiatric disorders. Delivered as a nasal spray, esketamine is a pure ketamine substance that has been indicated for major depressive disorder (MDD). Some patients report immediate relief from suicidal ideations, although the greater scientific community is not completely convinced due to the small effect size.

Clinicians are also promoting the use of psilocybin (the active ingredient in magic mushrooms) as a means to increase the patient’s receptivity to talk therapy. A quick search of the ClinicalTrials.gov site reveals that there are 53 ongoing human clinical studies on the therapeutic effects of psilocybin for a wide range of diseases, from anorexia to cancer. Leading the way, a Phase 2 study (N=80; NCT03866174) investigating the antidepressive effects of a single-dose psilocybin administration is currently being conducted by the Usona Institute and was recently granted “Breakthrough Designation”. Compass Pathways is also currently conducting a Phase 2b study (N=216, NCT03775200) for the use of psilocybin in treating treatment resistant depression.

The Multidisciplinary Association for Psychedelics Studies (MAPS) recently raised $30M for its MDMA study in the treatment of PTSD . Granted the “Breakthrough Therapy” designation by the FDA. MAPS’ Phase 3 clinical trials are ongoing with expected approval as early as 2022 . There are 90 other trials currently being conducted on MDMA.

SOURCE: https://www.medicalgold.ca/posts/psychedelics-from-woodstock-to-walgreens

Thoughtful Brands $TBI.ca Announces Binding Letter of Intent for Reverse-Takeover of Franchise Cannabis $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $SHRM.ca $RVV.ca $NOVA.ca

Posted by AGORACOM-Eric at 3:02 PM on Thursday, January 7th, 2021
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564664/hub/Throught_brands_logo.png
  • Franchise Cannabis, a leading European medical cannabis company, to complete public listing with strategic expansion into other cannabis markets.
  • Combined company will be well positioned to expand product offerings and distribution channels in the US and Europe.

Thoughtful Brands Inc. (“TBI“) (CSE:TBI)(FSE:1WZ1)(OTCQB:PEMTF) and Franchise Cannabis Corp. (“FCC“) are pleased to announce that they have entered into a binding letter of intent (the “Letter of Intent“), dated January 6, 2021, to consummate a going-public transaction for FCC involving the reverse-takeover of TBI (the “Transaction“).

The Transaction will involve the acquisition of all of the outstanding share capital of FCC by TBI, with the resulting Canadian reporting company being listed on the Canadian Securities Exchange (the “CSE“) under the name “Franchise Cannabis Corp.” (the “Resulting Issuer“). The Transaction is expected to be highly-accretive as both companies look to build on their complementary expertise to grow their respective businesses within the United States and Europe.

RESULTING ISSUER FOOTPRINT

Following completion of the Transaction, the Resulting Issuer, through its operating subsidiaries will have two German medical cannabis distribution businesses, a registered cannabis genetics subsidiary in Denmark, cultivation and strategic supply agreements on three continents, and a rapidly growing pharmaceutical distribution business with sales to over 18 countries combined with a high revenue CBD eCommerce platform. In addition, the Resulting Issuer will have a US based CBD extraction facility. Together TBI and FCC remain devoted to building on the growing pharmaceutical distribution platform in Europe while expanding sales channels through its regulated medical cannabis business in Europe and the consumer-focused CBD eCommerce division in North America and expansion to Europe. Management believes the combined companies’ assets are synergistic as they combine expertise and access to the two largest medical cannabis and consumer CBD markets, being the United States and Europe.

Read More: https://agoracom.com/ir/ThoughtfulBrands/forums/discussion/topics/752558-thoughtful-brands-announces-binding-letter-of-intent-for-reverse-takeover-of-franchise-cannabis/messages/2296520#message

Red Light Holland $TRIP.ca Engages Graham Pechenik, Respected Patent and IP Lawyer and Editor-at-Large of Psilocybin Alpha, as Senior Advisor to Advisory Board $SHRM.ca $RVV.ca $MMED $PLNT.ca $HALO.ca $PSYC.ca

Posted by AGORACOM-Eric at 9:09 AM on Thursday, December 31st, 2020
https://i.ibb.co/ZdKv64V/Red-Light-Holland-Square.jpg

 Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC: TRUFF) (“Red Light Holland“) is pleased to announce it has engaged Graham Pechenik to serve as a Senior Advisor to its Advisory Board. Graham is a registered patent attorney, with degrees in Biochemistry and Cognitive Neuroscience. Mr Pechenik gained over a decade of experience representing Fortune 500 companies in the agricultural, chemical, pharmaceutical, biotech, and technology industries before founding Calyx Law in 2016, the first intellectual property law boutique to focus on cannabis and psychedelics. Graham is also editor-at-large of Psilocybin Alpha, where he tracks patent filings and writes about patent issues in the psychedelics space. 

“Adding Graham Pechenik, who is a well-respected lawyer who develops IP strategies, protects IP through patent and trademark filings, and uses IP to generate value and growth, coupled with his strong support and advocacy of responsible use of psychedelics, to Red Light Holland’s Advisory Board, as a Senior Advisor, is another magical moment for the Company,” said Todd Shapiro, the Chief Executive Officer and Director of Red Light Holland. “During the last seven months we have compiled an incredible Advisory Board, including our chair Bruce Linton. Graham was, simply put, another desired piece of the puzzle we were searching for to help round out this very important and active team. We are elated to have Graham join Red Light Holland and our visions of providing responsible legal access of psilocybin, through education and information align tremendously.”

“Having experienced firsthand the benefits of psilocybin mushrooms and microdosing, including for issues involving anxiety, alcohol use, and attention, I’m a strong supporter of making these benefits I’ve seen personally (without making medical claims) available to responsible adults everywhere,” said Graham Pechenik, Founder of Calyx Law. “However, even just discussing the use of mushrooms is heavily stigmatized in most places. I look forward to the day when psilocybin mushrooms and truffles are hopefully more legally accessible, and I am thrilled to help Red Light Holland raise awareness of the magic truffle worldwide. I’m honoured and delighted to work toward this vision with such a stellar team.”

In consideration for his services as Senior Advisor, and subject to all applicable laws (including the rules and policies of the Canadian Securities Exchange) (“Applicable Laws“) the Company has granted to Mr. Pechenik 250,000 incentive stock options (the “Options” and each individually, the “Option“). Each Option will entitle the holder thereof to acquire one common share in the capital of Company for a period of three years from the date of issuance, at an exercise price of $0.315 CND. The Options shall be subject to Applicable Laws and the terms and conditions of the Stock Option Plan of the Company.  

About Red Light Holland Corp.

The Company is an Ontario-based corporation engaged in the production, growth and sale (through existing Smart Shops operators and an advanced e-commerce platform) of a premium brand of magic truffles to the legal, recreational market within the Netherlands, in accordance with the highest standards, in compliance with all applicable laws.

For additional information on the Company:

Todd Shapiro
Chief Executive Officer, Chairman, and Director
Tel: 647-204-7129
Email: [email protected]
Website: https://redlighttruffles.com/

Red Light Holland $TRIP.ca To Make Groundbreaking Investment in St. Vincent and the Grenadines’ Plant-Based Wellness and Psychedelics Industry $SHRM.ca $RVV.ca $MMED $PLNT.ca $HALO.ca $PSYC.ca

Posted by AGORACOM-Eric at 8:54 AM on Wednesday, December 30th, 2020
https://i.ibb.co/ZdKv64V/Red-Light-Holland-Square.jpg

Toronto, Ontario–(Newsfile Corp. – December 30, 2020) – Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC: TRUFF) (“Red Light Holland” or the “Company“), is pleased to announce it has entered into a non-binding letter of intent to acquire 100% of Mera Life Sciences LLC (“Mera“), a company focused on developing a modern medicinal industry in St Vincent and the Grenadines, with their issued Psychedelic Licenses, which includes the following plants and compounds (the “Compounds”): (i) Mushrooms/Truffles – Psilocybin; (ii) Ketamine; (iii) Ayahuasca; (iv) 3,4-Methyl​enedioxy​methamphetamine (MDMA); (v) 5-methoxy-N,N-dimethyltryptamine (5-MEO-DMT); (vi) Dimethyltryptamine (DMT); (vii) Sassafras; (viii) Ibogaine; (ix) Peyote (x) Papaya; (xi) Aloe Vera; (xii) Arrowroot; (xiii) Soursop; (xiv) Ginger; (xv) Moringa; and (xvi) Coconut Oil.

“The acquisition of Mera and its coveted licenses would allow Red Light Holland to perform high quality psychedelic product research and development, cultivate, extract and process, and export not just Psilocybin, but with compounds such as Ayahuasca, MDMA, DMT, Peyote, Ketamine and many other natural based plants as well. We are The People’s Company and we want to work closely with countries wishing to develop plant and fungus-based remedies – including treatment clinics, and we now understand that St. Vincent and the Grenadines shares our vision.” said Todd Shapiro, CEO and Director of Red Light Holland.

As well, the terms of the agreement will permit Red Light Holland to collaborate with Vincentian entities to import any of the above Compounds.

“The opportunity to explore the inner molecular worlds of multiple plant species, including a variety of psychedelics, is an exciting one. This could put Red Light Holland in the position to discover novel clinical applications for a variety of natural psychedelics. By utilizing a lab built for this purpose on the (main) island, along with cutting edge artificial intelligence, something I’m very familiar with, Red Light Holland would be approaching the frontier of natural plant based drug discovery,” said Dr. Joseph Geraci, Scientific Advisor of Red Light Holland and CEO of NetraMark Corp.

“Red Light Holland is focused on establishing itself as a multi country operator with natural plants and natural fungi, from growing to distribution of legal sales to potential clinics. We look forward to the careful due diligence process and hopefully adding Mera and their ground-breaking licenses in SVG, which would instantly strengthen our Scientific and Innovation Division, Scarlette Lillie by expanding our vision for research and development and for providing access to natural psychedelics on all fronts,” added Shapiro.

“The emerging modern plant-based medicinal research industry in the Caribbean is the future, and St. Vincent and the Grenadines is leading on this path” The island’s Minister of Agriculture, Hon. Saboto Caesar pointed out. “St. Vincent and the Grenadines has been able to attract experts interested in exploring the medicinal value of indigenous plants, cannabis and other plants that may thrive in tropical conditions and possess medicinal properties.” re-expressed from News 784.

Further details will be announced once made available.

About Mera Life Sciences LLC

Mera Life Sciences LLC is focused on the research and development, cultivation, extraction, processing and completion, exportation and clinics using natural medicines. Mera holds the ability to work with a number of psychedelic substances as part of the previously announced medicinal feasibility study.

About Red Light Holland Corp.

The Company is an Ontario-based corporation positioning itself to engage in the production, growth and sale (through existing Smart Shops operators and an advanced e-commerce platform) of a premium brand of magic truffles to the legal market within the Netherlands, in accordance with the highest standards, in compliance with all applicable laws.

For additional information on the Company:

Todd Shapiro
Chief Executive Officer & Director
Tel: 647-204-7129
Email: [email protected]
Website: https://redlighttruffles.com/